Subtype
Digestive System Neuroendocrine Tumor
CI-CAN-00000823Explore in graph →
Non-malignant62 active trials1 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000823Explore in graph →
Clinical trials
256 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05554744 | EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors | unknown | N/A | 20 | Guangxi Medical UniversityOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT01229943 | Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery | completed | Phase 2 | 150 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2022 | clinicaltrials |
| NCT02358356 | Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study(CONTROL NETS) | completed | Phase 2 | 75 | Australasian Gastro-Intestinal Trials GroupNETWORK | 1 | Jul 5, 2022 | clinicaltrials |
| NCT05429216 | Endoscopic Resection for Small Rectal Neuroendocrine Tumors | not yet recruiting | N/A | 102 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Jul 1, 2022 | clinicaltrials |
| NCT03741517 | Biomarker Study of Pancreatic Neuroendocrine Tumours | unknown | — | 40 | Uppsala UniversityOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT02586844 | Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors(NET-SEQ) | completed | — | 13 | University Health Network, TorontoOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT03147768 | Laser Tissue Welding - Distal Pancreatectomy Sealing Study(LTW) | completed | Phase 1 | 11 | Laser Tissue Welding, Inc.INDUSTRY | 1 | Apr 6, 2022 | clinicaltrials |
| NCT01747096 | TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors(68-DOTANOC-GEP) | completed | N/A | 130 | Nantes University HospitalOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT02259725 | Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors | completed | Phase 2 | 3 | University of Southern CaliforniaOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT02630654 | Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs(EXPLAIN) | completed | — | 404 | IpsenINDUSTRY | 7 | Dec 7, 2021 | clinicaltrials |
| NCT01869725 | Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT | completed | Phase 2 | 68 | Sue O'DorisioOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT01465659 | Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 29 | Northwestern UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT02948946 | Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors | completed | — | 105 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT03189953 | 68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH(GLP-1-AHH) | completed | Phase 1 / Phase 2 | 56 | Radboud University Medical CenterOTHER | 0 | Jun 16, 2021 | clinicaltrials |
| NCT03947762 | Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.(PanNET) | terminated | — | 54 | IpsenINDUSTRY | 2 | Jun 14, 2021 | clinicaltrials |
| NCT03053284 | Pasireotide in Hyperinsulinemic Hypoglycemia | withdrawn | Phase 2 | 0 | Montefiore Medical CenterOTHER | 0 | May 14, 2021 | clinicaltrials |
| NCT02853422 | Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine Tumours(QUALINETS) | completed | — | 199 | IpsenINDUSTRY | 2 | Nov 5, 2020 | clinicaltrials |
| NCT02420691 | Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin | completed | Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT02355535 | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 | completed | Phase 1 | 48 | Vanquish Oncology, Inc.INDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT02575300 | Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 11, 2020 | clinicaltrials |
| NCT00576680 | RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors | completed | Phase 1 / Phase 2 | 43 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 9, 2020 | clinicaltrials |
| NCT02730104 | Community-based Neuroendocrine Tumor (NET) Research Study | completed | — | 100 | IpsenINDUSTRY | 1 | Jun 26, 2020 | clinicaltrials |
| NCT02788565 | Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours(STREET) | completed | — | 156 | IpsenINDUSTRY | 1 | Jun 2, 2020 | clinicaltrials |
| NCT00454363 | Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2020 | clinicaltrials |
| NCT02841865 | Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria(CRIPNET) | completed | — | 104 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Mar 24, 2020 | clinicaltrials |
| NCT04065165 | Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome(TELEFIRST) | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Feb 5, 2020 | clinicaltrials |
| NCT04185350 | Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma | unknown | Early Phase 1 | 60 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Dec 4, 2019 | clinicaltrials |
| NCT04134832 | Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region | unknown | — | 250 | University Hospital, Strasbourg, FranceOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT02162446 | 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET | completed | Phase 1 / Phase 2 | 12 | IpsenINDUSTRY | 1 | Oct 2, 2019 | clinicaltrials |
| NCT03053999 | Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET) | unknown | — | 53 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01648465 | Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors | terminated | Phase 2 | 25 | Hellenic Cooperative Oncology GroupOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT00428220 | A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. | completed | N/A | 223 | PfizerINDUSTRY | 17 | Jun 27, 2019 | clinicaltrials |
| NCT03982264 | Endoscopic Treatment of Rectal Neuroendocrine Tumor(NET) Less Than 10mm | unknown | N/A | 90 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Jun 11, 2019 | clinicaltrials |
| NCT03963193 | Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type | unknown | Phase 2 | 112 | Henan Cancer HospitalOTHER_GOV | 0 | May 24, 2019 | clinicaltrials |
| NCT02231762 | Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET(SONNET) | completed | Phase 2 | 57 | IpsenINDUSTRY | 2 | May 6, 2019 | clinicaltrials |
| NCT03930368 | Application of Raw Corn Starch on Patients With Insulinoma | unknown | N/A | 20 | Peking Union Medical College HospitalOTHER | 1 | Apr 29, 2019 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT03812939 | Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs | unknown | — | 30 | Peking Union Medical College HospitalOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01994213 | A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor | terminated | Phase 2 | 53 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 22, 2019 | clinicaltrials |
| NCT03017690 | Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) | completed | — | 22 | IpsenINDUSTRY | 1 | Dec 21, 2018 | clinicaltrials |
| NCT00019474 | Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer | completed | Phase 2 | 60 | Montefiore Medical CenterOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT03442959 | Resection of the Primary Tumor vs no Resection in Asymptomatic Patients With Unresectable Synchronous Liver Metastases From siNEN(SI-NET) | unknown | — | 50 | CHU de ReimsOTHER | 1 | Jul 12, 2018 | clinicaltrials |
| NCT01024387 | AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 8, 2018 | clinicaltrials |
| NCT03435770 | Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms | unknown | N/A | 10 | Singapore General HospitalOTHER | 1 | Feb 20, 2018 | clinicaltrials |
| NCT03417843 | Safety and Efficacy of an Ablation Catheter for the Treatment of Pancreatic Premalignant Cyctic Lesions.(yes) | unknown | N/A | 20 | HaEmek Medical Center, IsraelOTHER | 0 | Feb 13, 2018 | clinicaltrials |
| NCT00903396 | Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer | terminated | Phase 2 | 7 | Alliance for Clinical Trials in OncologyOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Sep 28, 2017 | clinicaltrials |
| NCT00730483 | Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors | terminated | N/A | 13 | Yale UniversityOTHER | 1 | Aug 25, 2017 | clinicaltrials |
| NCT01980732 | 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors | no longer available | — | — | Andrei IagaruOTHER | 1 | Aug 23, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Sep 27, 2022source: clinicaltrials